Browse our latest Microbiology and Infectious Disease articles

Integrative analyses uncover RBMX2 as a pivotal mediator that bridges Mycobacterium bovis infection to epithelial–mesenchymal transition and tumor progression in the lung.

The development of new small molecules demonstrates how pharmacologic inhibition of the coronavirus macrodomain restores innate immunity, leading to reduced viral replication and improved outcomes in severe infection.

Unraveling mechanisms underlying post-acute SARS-CoV-2 sequelae (long COVID) and finding therapeutic solutions require a full understanding of the causative role of SARS-CoV-2 persistence and/or infection with other microorganisms, which may be pre-existing, concurrent, or subsequent to acute COVID-19.

Epigenetic and metabolic programming of innate immune cells shapes host defense and disease susceptibility.

Classical antibody boosting effects during vaccination are accompanied by natural broadening mechanisms that help enable human antibodies to engage conserved sites of vulnerability on influenza virus.